These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38460798)

  • 1. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
    Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
    Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.
    Martinez-Baquero D; Sakhdari A; Mo H; Kim DH; Kanagal-Shamanna R; Li S; Young KH; O'Malley DP; Dogan A; Jain P; Wang ML; McDonnell TJ; Miranda RN; Vega F; Medeiros LJ; Ok CY
    Mod Pathol; 2021 Dec; 34(12):2183-2191. PubMed ID: 34376807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
    Jing C; Zheng Y; Feng Y; Cao X; Xu C
    Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.
    Kim DH; Medeiros LJ; Aung PP; Young KH; Miranda RN; Ok CY
    Am J Surg Pathol; 2019 Oct; 43(10):1421-1428. PubMed ID: 31219818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
    Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.
    Aukema SM; Hoster E; Rosenwald A; Canoni D; Delfau-Larue MH; Rymkiewicz G; Thorns C; Hartmann S; Kluin-Nelemans H; Hermine O; Dreyling M; Klapper W
    Blood; 2018 Jan; 131(4):417-420. PubMed ID: 29196411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
    Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
    Chiarle R; Budel LM; Skolnik J; Frizzera G; Chilosi M; Corato A; Pizzolo G; Magidson J; Montagnoli A; Pagano M; Maes B; De Wolf-Peeters C; Inghirami G
    Blood; 2000 Jan; 95(2):619-26. PubMed ID: 10627471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mantle cell lymphoma shows three morphological evolutions of classical, intermediate, and aggressive forms, which occur in parallel with increased labeling index of cyclin D1 and Ki-67.
    Kimura Y; Sato K; Arakawa F; Karube K; Nomura Y; Shimizu K; Aoki R; Hashikawa K; Yoshida S; Kiyasu J; Takeuchi M; Nino D; Sugita Y; Morito T; Yoshino T; Nakamura S; Kikuchi M; Ohshima K
    Cancer Sci; 2010 Mar; 101(3):806-14. PubMed ID: 20002441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
    Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
    Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.
    Neves Filho EH; Hirth CG; Frederico IA; Burbano RM; Carneiro T; Rabenhorst SH
    APMIS; 2020 Apr; 128(4):308-315. PubMed ID: 31991488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
    Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
    J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.
    Dong HJ; Zhou LT; Fang C; Fan L; Zhu DX; Wang YH; Li JY; Xu W
    Med Oncol; 2012 Sep; 29(3):2166-73. PubMed ID: 22057359
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
    Delfau-Larue MH; Klapper W; Berger F; Jardin F; Briere J; Salles G; Casasnovas O; Feugier P; Haioun C; Ribrag V; Thieblemont C; Unterhalt M; Dreyling M; Macintyre E; Pott C; Hermine O; Hoster E;
    Blood; 2015 Jul; 126(5):604-11. PubMed ID: 26022239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.
    Slotta-Huspenina J; Koch I; de Leval L; Keller G; Klier M; Bink K; Kremer M; Raffeld M; Fend F; Quintanilla-Martinez L
    Haematologica; 2012 Sep; 97(9):1422-30. PubMed ID: 22315488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
    Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
    Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomas.
    Liu B; Pang B; Wang Q; Yang S; Gao T; Ding Q; Liu H; Yang Y; Fan H; Zhang R; Xin T; Xu G; Pang Q
    Hum Pathol; 2017 Aug; 66():101-107. PubMed ID: 28666925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.